CinDome Pharma has hit a critical milestone in the race to tackle a long-overlooked digestive disorder, announcing it has completed patient enrollment in its mid-stage clinical trial for a potential breakthrough treatment.

 

The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis—a chronic condition affecting an estimated 16 million Americans that currently has no FDA-approved long-term therapy. With enrollment now closed, the company says topline safety and efficacy results are expected in the second half of 2026.

 

The moment marks a significant step forward not just for the company, but for patients who have long faced limited and imperfect treatment options.

 

“With the completion of enrollment for envisionGI, we’ve reached another important milestone for deudomperidone and most importantly for patients with idiopathic gastroparesis who need a chronic treatment option for this debilitating condition,” said Brian Murphy, Chief Medical Officer of CinRx Pharma. 

 

“Deudomperidone has the potential to be a transformative treatment for millions of patients, as the first safe, long-term therapy that could significantly improve gastroparesis symptoms, including reducing the severity of nausea and vomiting, and increasing the number of symptom-free days. We are encouraged by the interim, blinded data we’ve seen so far. We look forward to sharing the full data readout later this year.”

 

Deudomperidone is a next-generation version of domperidone, a drug widely used outside the United States to treat nausea and gastroparesis but barred domestically due to safety concerns linked to heart rhythm abnormalities. 

 

CinDome says its reformulated compound is engineered to lower peak drug concentration and extend its activity in the body—potentially delivering similar or improved benefits with fewer cardiac risks.

 

Medical experts say the stakes are high.

 

“Deudomperidone has the potential to address a significant unmet medical need for patients struggling with gastroparesis and its symptoms, and for physicians who lack effective treatments,” said Henry P Parkman, Gastroenterology, Lewis Katz School of Medicine at Temple University. 

 

“The envisionGI study is critical to demonstrating the potential of this new treatment option and how it will positively impact patients’ lives both in the near and long-term.”